Program
FXS5626
A development code. Also written as “FXS5626 tablet”, “Intervention1: FXS5626 Tablets” and “Intervention2: FXS5626 Tablets”.
In Fosun Pharma's pipeline, TYK2/JAK1
. Its studies are mostly in Uveitis · Vitiligo, led by Fosun Pharma.
Furthest: phase 3, since Sep 17, 20263 company-led studies, 3 open or runningNext primary completion: Feb 28, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fosun Pharma | 33 open or running | phase 3since Sep 17, 2026 | Mar 11, 2026 | Feb 28, 2027phase 2 · NCT07552012 |
- Named in Fosun Pharma’s own pipeline as
FXS5626 (TYK2/JAK1)
, phase 2, as of Sep 21, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 11, 2026First study: phase 2 study in UveitisFirst studyNCT07552012 · 40 planned · China
- Jul 6, 2026Phase 1 study in Evaluation of QTc IntervalNCT07695779 · 28 planned · China
- Sep 17, 2026Phase 3 study in Non-segmental VitiligoPhase 3 reachedNCT07840820 · 480 planned · China
Ahead
- Feb 28, 2027Primary completion: phase 2 study in UveitisNCT07552012
- Nov 10, 2027Primary completion: phase 3 study in Non-segmental VitiligoNCT07840820
TargetBeta
“TYK2/JAK1”the company's pipeline, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| brepocitinibrule | Pfizer | phase 3 | 25 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07840820Non-segmental Vitiligo · China | 3 | Not yet recruiting | Nov 10, 2027 | 480 |
| NCT07695779Evaluation of QTc Interval · China | 1 | Recruiting | Sep 21, 2026 | 28 |
| NCT07552012Uveitis · China | 2 | Recruiting | Feb 28, 2027 | 40 |
How it is read
Names in the registry
- “FXS5626 tablet”, 2 entries
- “Intervention1: FXS5626 Tablets”, 1 entry
- “Intervention2: FXS5626 Tablets”, 1 entry
- “Intervention3: FXS5626 Tablets”, 1 entry
- “Intervention4: FXS5626 Tablets”, 1 entry
Codes read as this program: FXS5626.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.